InvestSMART

Radiopharm Theranostics Limited (ASX:RAD)

ALERT: Price-sensitive ASX Announcement for RAD
Current share price for RAD : $0.013 -0.007 (-35%)+
Announcement
Release
27 Mar 2026 8:23AM
Price at Release
$0.020
Full Release
download
Summary
Radiopharm Theranostics Limited, a clinical-stage biopharmaceutical company, announced the dosing of the first patient in a Phase 1 clinical trial of RAD 402 for advanced prostate cancer. RAD 402 is a monoclonal antibody targeting KLK3, radiolabeled with Terbium 161. The trial aims to assess the safety, tolerability, whole-body distribution, and preliminary clinical activity, with the goal of determining the Maximum Tolerated Dose or recommended Phase 2 dose. The preclinical studies exhibited strong tumor targeting with minimal bone/marrow uptake, and the first patient dosing is a significant milestone for the company. The trial reflects Radiopharm's commitment to developing innovative radiotherapies and advancing clinical programs that address high unmet medical needs.
Key Points
  • First patient dosed in Phase 1 trial of RAD 402 for prostate cancer.
  • RAD 402 targets KLK3, radiolabeled with Terbium 161.
  • Trial to assess safety, tolerability, and clinical activity.
  • Goal to determine Maximum Tolerated Dose and recommended Phase 2 dose.
  • Preclinical studies showed strong tumor targeting.
  • Milestone reflects commitment to innovative radiotherapies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.